Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
HOTHNEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced over the last several days investors have contacted the...
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
HOTHChinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company...
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
HOTHNEW YORK, Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's...
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
HOTHNEW YORK, Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly...
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
HOTHNEW YORK, Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting...
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
HOTH(NASDAQ:HOTH) NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy...
Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
HOTH(NASDAQ:HOTH) NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor...
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
HOTHNEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid price requirement. On June 18, 2025, the Company...
Hoth Therapeutics Secures Japan Patent For HT-KIT Platform, Granted Exclusive Protection Until Aug. 27, 2039
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics Announces Expanded Access Initiative For HT-001, Offering Critical Relief To Cancer Patients Facing Severe Skin Toxicities
HOTHHoth Therapeutics Announces Key Opinion Leader Event Showcasing HT-001, Topical Therapeutic, Designed To Treat Debilitating Skin Toxicities Caused By EGFR Inhibitor Cancer Therapies
HOTHHoth Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 25%
HOTHHoth Therapeutics Announces Preclinical Data For HT-KIT, With IND Filing Expected In Early 2026; Says 'HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.'
HOTHHoth Therapeutics Granted Japanese Patent Expanding Global Intellectual Property Portfolio In RNA-based Cancer Therapeutics
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics Announces Initial Data In CLEER-001 Phase 2a Clinical Trial Of HT-001; Says Patients Experienced A 50% Reduction In Pruritus Severity, With Mean Scores Dropping From 1.6 On Day 1 To 0.8 By Day 21
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics Reports Preclinical Data On Lead Alzheimer's Candidate, HT-ALZ; Says Results Underscore Dual-Action Profile Of HT-ALZ—Impacting Both Pathology And Symptomology
HOTHHoth Therapeutics Secures USPTO Filing Receipt For HT-001 Formulation Patent Application
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics Announces Major Advancements For HT-KIT, Filing Amended Claims For Enhanced IP Protection And Initiating GLP-Compliant Preclinical Toxicity Study To Support Regulatory Filings For Its ASO Cancer Drug Candidate Targeting Allergic Inflamma
HOTHHoth Therapeutics Announces Preclinical Results For HT-KIT In Aggressive Cancer Gastrointestinal Stromal Tumors; Says HT-KIT Triggered Significant Tumor Cell Death As Early As 24 Hours Post-Treatment
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics To Submit Expanded Access Application For HT-001
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics Announces Results For HT-001
HOTHD. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
HOTHHoth Therapeutics Announces Preclinical Findings On Potential Of Glial Cell Line-Derived Neurotrophic Factor; Says Findings Include Protection Against High-Fat Diet-Induced Obesity, Enhanced Fat Burning and Energy Expenditure, Adipogenesis, Improved Insul
HOTHHoth Therapeutics Announced That The Company's Board Of Directors Approved The Purchase Of Up To $1M In Bitcoin
HOTHHoth Therapeutics Has Been Granted U.S. Patent No. 12,144,815 Titled USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE.
HOTHHC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
HOTHHoth Therapeutics Receives Notification Of Non-compliance With Nasdaq Minimum Bid Price Requirements
HOTHHoth Therapeutics Reports Prelim. Efficacy Findings From Phase 1b Trial With Mild To Moderate Atopic Dermatitis In Patient Cohort
HOTH